| Gene symbol | CLDN18 | Synonyms | SFTA5, SFTPJ | Type of gene | protein-coding | |
| Chromosome | 3 | Map location | 3q22.3 | dbXrefs | Entrez:51208 MIM:609210 HGNC:HGNC:2039 Ensembl:ENSG00000066405 AllianceGenome:HGNC:2039 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | claudin 18 | |||||
| Gene symbol | KLRK1 | Synonyms | CD314, D12S2489E, KLR, NKG2-D, NKG2D | Type of gene | protein-coding | |
| Chromosome | 12 | Map location | 12p13.2 | dbXrefs | Entrez:22914 MIM:611817 HGNC:HGNC:18788 Ensembl:ENSG00000213809 AllianceGenome:HGNC:18788 | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | killer cell lectin like receptor K1 | |||||
| GTO ID | GTC3663 |
| Trial ID | NCT06134960 |
| Disease | Gastric Cancer | Pancreatic Cancer |
| Altered gene | NKG2D|CLDN18 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KD-496 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors |
| Year | 2023 |
| Country | China |
| Company sponsor | Peking University |
| Other ID(s) | KD-496-01 |
| Cohort 1 | |||||||||
|
|||||||||